… drug resistance and the problem of mycobacterial persistence highlight the need to develop
novel TB drugs that are active against drug … shorten the length of treatment. Recent new and …

… treatment regimens should be individualised for each patient. A history of relapse after
discontinuation of drug treatment … a patient was unresponsive initially to drug treatment, or that dis…

… the number of drugs that may be registered by regulatory authorities, the time to discover
and develop drugs, and the cost of drug development. Because drug development has been …

… The aim of the present review is to discuss the potential value of therapeutic drug … in
ascertaining drug compliance, attributing toxicity to drug treatment, and in managing drug overdose. …

… many combinations of mutations, exist when a selective pressure like drug treatment is
introduced. Drug-resistance mutations to nucleosides, non-nucleoside reverse transcriptase …

… of VDAs with antiangiogenic drugs [77]. Overall, the observed antitumor efficacy of CA1P in
animal models supports the development of this drug as a stand-alone therapy, as well as in …

… establish data on developmental pharmacodynamics are necessary to achieve optimal
drug therapy in children and to ensure long-term success of pediatric drug development. This …

… In addition, we briefly survey several novel drug classes in development, provide summary
recommendations for glucose-lowering regimens in specific patient types, underscore the …

… of drugs, thus potentially leaving this aspect of tuberculosis therapy development unresolved
… How studies to identify the best new drug combinations for the treatment of both DS and DR …

… Thus, we should view drug development as a model building exercise during which we …
and use this knowledge to inform our decision-making and drug development strategy. …